Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response
Ben Sidders, Pei Zhang, Kelly Goodwin, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 9, pp. 2176-2187
Closed Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

The adenosine pathway in immuno-oncology
Bertrand Allard, David Allard, Laurence Buisseret, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 10, pp. 611-629
Closed Access | Times Cited: 396
Targeting CD39 in cancer
Achim K. Moesta, Xian-Yang Li, Mark J. Smyth
Nature reviews. Immunology (2020) Vol. 20, Iss. 12, pp. 739-755
Closed Access | Times Cited: 250
Antitumour immunity regulated by aberrant ERBB family signalling
Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa
Nature reviews. Cancer (2021) Vol. 21, Iss. 3, pp. 181-197
Closed Access | Times Cited: 202
ATP and cancer immunosurveillance
Oliver Kepp, Lucillia Bezu, Takahiro Yamazaki, et al.
The EMBO Journal (2021) Vol. 40, Iss. 13
Open Access | Times Cited: 156
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Jacob Stultz, Lawrence Fong
Prostate Cancer and Prostatic Diseases (2021) Vol. 24, Iss. 3, pp. 697-717
Open Access | Times Cited: 146
CD39/CD73/A2AR pathway and cancer immunotherapy
Chenglai Xia, Shuanghong Yin, Kenneth K.W. To, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 141
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Huailiang Wu, Yue Gong, Peng Ji, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 106
The functional roles of the circRNA/Wnt axis in cancer
Chen Xue, Ganglei Li, Qiuxian Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 93
ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain
Gennady G. Yegutkin, Detlev Boison
Pharmacological Reviews (2022) Vol. 74, Iss. 3, pp. 799-824
Open Access | Times Cited: 87
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
Ryan C. Augustin, Robert D. Leone, Aung Naing, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 2, pp. e004089-e004089
Open Access | Times Cited: 78
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 22, pp. 4871-4884
Open Access | Times Cited: 44
The Immune Regulatory Role of Adenosine in the Tumor Microenvironment
Jianlei Xing, Jinhua Zhang, Jinyan Wang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14928-14928
Open Access | Times Cited: 30
The Clinical Significance of CD73 in Cancer
Niklas Bach, Riekje Winzer, Eva Tolosa, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11759-11759
Open Access | Times Cited: 27
The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy
John Stagg, Encouse B. Golden, Erik Wennerberg, et al.
Science Immunology (2023) Vol. 8, Iss. 85
Open Access | Times Cited: 23
Discovery of the First Efficacious Adenosine 2A Receptor Negative Allosteric Modulators for High Adenosine Cancer Immunotherapies
Margot Boujut, Margaux Héritier, Aurélie Gouiller, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
CD73, Tumor Plasticity and Immune Evasion in Solid Cancers
Haitang Yang, Feng Yao, Paul F. Davis, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 177-177
Open Access | Times Cited: 48
CD39 – A bright target for cancer immunotherapy
Shuwei Guo, Fengfeng Han, Wei Zhu
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113066-113066
Open Access | Times Cited: 35
Emerging Biosensing Methods to Monitor Lung Cancer Biomarkers in Biological Samples: A Comprehensive Review
Raja Chinnappan, Tanveer Ahmad Mir, Sulaiman Alsalameh, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3414-3414
Open Access | Times Cited: 21
Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
Zoya Kurago, Gang Guo, Huidong Shi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Pharmacology of Adenosine Receptors: Recent Advancements
Fabrizio Vincenzi, Silvia Pasquini, Chiara Contri, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1387-1387
Open Access | Times Cited: 16
Nociceptive adenosine A2A receptor on trigeminal nerves orchestrates CGRP release to regulate the progression of oral squamous cell carcinoma
Lanxin Jiang, Ying Zhou, Shijie Tang, et al.
International Journal of Oral Science (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 6
Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance
Anna Passarelli, Michele Aieta, Alessandro Sgambato, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 44
Targeting the A2AR in cancer; early lessons from the clinic
Stephen B. Willingham, Andrew Hotson, Richard A. Miller
Current Opinion in Pharmacology (2020) Vol. 53, pp. 126-133
Open Access | Times Cited: 40
Immunosuppressive metabolites in tumoral immune evasion: redundancies, clinical efforts, and pathways forward
Maria Rain Jennings, David H. Munn, John Blazeck
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 10, pp. e003013-e003013
Open Access | Times Cited: 36
Research progress on the structure, function, and use of angiogenin in malignant tumours
Mingwen Mao, Weina Chen, Dong Ye
Heliyon (2024) Vol. 10, Iss. 9, pp. e30654-e30654
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top